macitentan

macitentan Struktur
441798-33-0
CAS-Nr.
441798-33-0
Englisch Name:
macitentan
Synonyma:
5-(4-BROMOPHENYL)-6-[2-(5-BROMOPYRIMIDIN-2-YL)OXYETHOXY]-N-(PROPYLSULFAMOYL)PYRIMIDIN-4-AMINE;CS-643;Maximitan;Masititan;ACT-064992;ACT 064992;macitentan;Actelion-1;Macitentan CRS;Macitentan, >=99%
CBNumber:
CB81518520
Summenformel:
C19H20Br2N6O4S
Molgewicht:
588.27
MOL-Datei:
441798-33-0.mol

macitentan Eigenschaften

Siedepunkt:
692.4±65.0 °C(Predicted)
Dichte
1.675
storage temp. 
Store at -20°C
Löslichkeit
≥24.4 mg/mL in DMSO; insoluble in H2O; insoluble in EtOH
Aggregatzustand
solid
pka
4.99±0.50(Predicted)
Farbe
White to off-white
InChI
InChI=1S/C19H20Br2N6O4S/c1-2-7-26-32(28,29)27-17-16(13-3-5-14(20)6-4-13)18(25-12-24-17)30-8-9-31-19-22-10-15(21)11-23-19/h3-6,10-12,26H,2,7-9H2,1H3,(H,24,25,27)
InChIKey
JGCMEBMXRHSZKX-UHFFFAOYSA-N
SMILES
S(NC1C(C2=CC=C(Br)C=C2)=C(OCCOC2=NC=C(Br)C=N2)N=CN=1)(NCCC)(=O)=O
Sicherheit
  • Risiko- und Sicherheitserklärung
  • Gefahreninformationscode (GHS)
Bildanzeige (GHS) GHS hazard pictograms
Alarmwort Achtung
Gefahrenhinweise
Code Gefahrenhinweise Gefahrenklasse Abteilung Alarmwort Symbol P-Code
H360 Kann die Fruchtbarkeit beeinträchtigen oder das Kind im Mutterleib schädigen. Fertility (Fruchtbarkeit) Kategorie 1 Achtung GHS hazard pictogramssrc="/GHS08.jpg" width="20" height="20" />
Sicherheit
P261 Einatmen von Staub vermeiden.
P264 Nach Gebrauch gründlich waschen.
P264 Nach Gebrauch gründlich waschen.
P271 Nur im Freien oder in gut belüfteten Räumen verwenden.
P280 Schutzhandschuhe/Schutzkleidung/Augenschutz tragen.
P302+P352 BEI BERÜHRUNG MIT DER HAUT: Mit viel Wasser/... (Hersteller kann, falls zweckmäßig, ein Reinigungsmittel angeben oder, wenn Wasser eindeutig ungeeignet ist, ein alternatives Mittel empfehlen) waschen.
P304+P340 BEI EINATMEN: Die Person an die frische Luft bringen und für ungehinderte Atmung sorgen.
P305+P351+P338 BEI KONTAKT MIT DEN AUGEN: Einige Minuten lang behutsam mit Wasser spülen. Eventuell vorhandene Kontaktlinsen nach Möglichkeit entfernen. Weiter spülen.
P312 Bei Unwohlsein GIFTINFORMATIONSZENTRUM/Arzt/... (geeignete Stelle für medizinische Notfallversorgung vom Hersteller/Lieferanten anzugeben) anrufen.
P321 Besondere Behandlung
P332+P313 Bei Hautreizung: Ärztlichen Rat einholen/ärztliche Hilfe hinzuziehen.
P337+P313 Bei anhaltender Augenreizung: Ärztlichen Rat einholen/ärztliche Hilfe hinzuziehen.
P362 Kontaminierte Kleidung ausziehen und vor erneutem Tragen waschen.
P403+P233 An einem gut belüfteten Ort aufbewahren. Behälter dicht verschlossen halten.

macitentan Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung

Macitentan (also known as ACT-064992) received US FDA approval in October 2013 for the treatment of pulmonary arterial hypertension (PAH) (WHO group I) to delay disease progression. Treatment options include phosphodiesterase type 5 inhibitors, prostacyclins, and the endothelin receptor antagonists bosentan and ambrisentan. Macitentan was discovered through SAR studies starting with the bosentan structure with three main goals: (1) to increase potency for both endothelin receptor A and B (ETA and ETB) subtypes; (2) to improve tissue distribution to reach the target receptors; and (3) to avoid bile salt transport inhibition. Starting with the bosentan sulfonamido-pyrimidinyl central core, potency was increased 10-fold via incorporation of a bromopyrimidinyl ethylene glycol ether, as found in the clinical endothelin antagonist, T-0201. An aryl ether in bosentan was replaced with the bromophenyl group in macitentan, and a substituent on the 2-position of the central pyrimidine was replaced with hydrogen. Several sulfonamides and alkyl sulfamates were explored, with the propylsulfamate providing the best combination of in vitro potency, especially for ETB antagonism, and in vivo efficacy.

Verwenden

Macitentan is an endothelin receptor antagonist that is used in the therapy of pulmonary arterial hypertension (PAH). It also reduced hospitalization for PAH. Macitentan was approved for PAH by the United States Food and Drug Administration (FDA) in 2013. Macitentan has been associated with a low rate of serum enzyme elevations during therapy, but has yet to be implicated in cases of clinically apparent acute liver injury.

Definition

ChEBI: Macitentan is a member of the class of sulfamides in which the two amino groups of sulfonamide are substituted by 5-(4-bromophenyl)-6-{2-[(5-bromopyrimidin-2-yl)oxy]ethoxy}pyrimidin-4-yl and propyl groups. An orphan drug used for the treatment of pulmonary arterial hypertension. It has a role as an endothelin receptor antagonist, an antihypertensive agent and an orphan drug. It is an organobromine compound, a member of pyrimidines, an aromatic ether, a ring assembly and a member of sulfamides. It is functionally related to an ethylene glycol and an ACT-132577.

Mode of action

Macitentan is an orally available dual endothelin receptor (ETR) antagonist with potential antihypertensive and antineoplastic activity. Upon administration, macitentan and its metabolites block the binding of endothelin isoform 1 (ET-1) to type-A and type-B ETR on both the tumor cells and the endothelial cells in the tumor vasculature. This prevents ET-1 mediated signaling transduction which may decrease tumor cell proliferation, progression, and angiogenesis in tumor tissue. ET-1, a potent vasoconstrictor that plays an important role in inflammation and tissue repair, is, together with its receptors, overexpressed varyingly in many tumor cell types.

macitentan Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte


macitentan Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global( 391)Lieferanten
Firmenname Telefon E-Mail Land Produktkatalog Edge Rate
Seasons Biotechnology Co., Ltd.
+86-0576-89232655 +86-13566878689
info@seasonsbio.com China 47 58
Unipharm pharmaceutical industry Co., Ltd
536-8266195 +8613953676784
lee@unipharm-sd.com China 1202 58
Hefei TianRui Pharmaceutical Chemical Co., Ltd.
+86-0551-68665055 +86-+86-18616906106
sales@trywchem.com China 183 58
Hebei Chuanghai Biotechnology Co., Ltd
+8615350571055
Sibel@chuanghaibio.com China 8768 58
Hebei Ganmiao New material Technology Co., LTD
+86-17332992504
sales8@hbganmiao.com China 300 58
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
+86-18600796368
sales@sjar-tech.com China 504 58
Capot Chemical Co.,Ltd.
+86-(0)57185586718; +8613336195806
sales@capot.com China 29735 60
Henan Tianfu Chemical Co.,Ltd.
+86-0371-55170693 +86-19937530512
info@tianfuchem.com China 21612 55
Shanghai Yingrui Biopharma Co., Ltd.
+86-21-33585366 - 03@
sales03@shyrchem.com CHINA 738 60
ATK CHEMICAL COMPANY LIMITED
+undefined-21-51877795
ivan@atkchemical.com China 33024 60

  • N-[5-(4-Bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)-oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfami
  • macitentan
  • N-[5-(4-Bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfamide
  • ACT 064992
  • ACT-064992
  • ACT-064992 / ACT064992
  • Macitentan, >=99%
  • SulfaMide,N-[5-(4-broMophenyl)-6-[2-[(5-broMo-2-pyriMidinyl)oxy]ethoxy]-4-pyriMidinyl]-N'-propyl-
  • N-[5-(4-Bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfamide Macitentan
  • macitentan,CID 16004692
  • CS-643
  • Macitentan (ACT 064992
  • Macitentan (Actelion-1,ACT-064992)
  • Actelion-1
  • macitentan ISO 9001:2015 REACH
  • Macitentan (ACT-064992 D4)
  • 5-(4-BROMOPHENYL)-6-[2-(5-BROMOPYRIMIDIN-2-YL)OXYETHOXY]-N-(PROPYLSULFAMOYL)PYRIMIDIN-4-AMINE
  • Marcy for Tanzania
  • {[5-(4-bromophenyl)-6-{2-[(5-bromopyrimidin-2-yl)oxy]ethoxy}pyrimidin-4-yl]sulfamoyl}(propyl)amine
  • Macitentan tablet 10mg
  • Maximitan
  • Macitentan CRS
  • N-(5-(4-Bromophenyl)-6-(2-((5-bromo-2-pyrimidinyl)oxy)ethoxy)-4-pyrimidinyl)-N'-propylsulfamide
  • Masititan
  • Macitentan, 10 mM in DMSO
  • Macitentan - Bio-X ?
  • 441798-33-0
  • C19H20Br2N6O4S
  • Inhibitors
  • API
  • 441798-33-0
Copyright 2019 © ChemicalBook. All rights reserved